Home › FDA Accepts for Review Mercks Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine
 

Keywords :   


FDA Accepts for Review Mercks Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine

2014-02-20 14:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration. About Merck Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: review application human license

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Tropical Storm Leslie Public Advisory Number 10
04.10Summary for Tropical Storm Leslie (AT3/AL132024)
More »